167 related articles for article (PubMed ID: 20590818)
1. Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Yamaki M; Sugiura K; Muro Y; Shimoyama Y; Tomita Y
Exp Dermatol; 2010 Aug; 19(8):730-5. PubMed ID: 20590818
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
3. Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Shin JU; Park JH; Cho BC; Lee JH
Dermatology; 2012; 225(2):135-40. PubMed ID: 23006507
[TBL] [Abstract][Full Text] [Related]
4. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
Lu PH; Kuo TC; Chang KC; Chang CH; Chu CY
Br J Dermatol; 2011 Jan; 164(1):38-46. PubMed ID: 20846305
[TBL] [Abstract][Full Text] [Related]
6. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
7. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
8. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
9. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
10. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
[TBL] [Abstract][Full Text] [Related]
12. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
[TBL] [Abstract][Full Text] [Related]
13. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Herbst RS; Bunn PA
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
[TBL] [Abstract][Full Text] [Related]
15. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Morgillo F; Kim WY; Kim ES; Ciardiello F; Hong WK; Lee HY
Clin Cancer Res; 2007 May; 13(9):2795-803. PubMed ID: 17473213
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
19. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
